The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.
Fotios Koumpouras, MD, FACR
Advertisement
Assistant Professor of Medicine
Director of Education and Training
Rheumatology Director, Yale Lupus Program
Yale School of Medicine
Articles by Fotios Koumpouras, MD, FACR
Advertisement
Latest Updated Articles
Systemic Lupus Erythematosus Treatment Advances: AnifrolumabPublished: March 18th 2022 | Updated:
Advertisement
Advertisement